Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Happy", Aleafia is not only already supplying union member, but they are wholesaling "lower-margin" cannabis right now. That's BEFORE the outdoor harvest later this month/early October.
Aleafia just doesn't have the flow through relationships and "in-demand" brands.
Right now IMO their great asset will be their low production cost which should be a big revenue boost in Q4 when the outdoor harvest translates into wholesale revenue.
But then what? Those 86 acres won't be planted again until next April/May.
I am very down on Aleafia.
They're already supplying to the union patients so you are saying a larger influx of patients is coming and if so, that could be why the offering and what they are doing? You may be correct.
I haven't stopped watching it. It didn't seem to want to go below .20 or very close to it.
I think they are shoring up their supply line for when the Union deal starts generating patients (and revenues) they may have to buy from other growers to meet demand until they have a full idea of uptake. They saw all the “big guys” get saddled with redundant assets so I would rather see them buy wholesale for a bit and tweak their supply line as needed. Total guess here but that is what I would do in their place.
I'm on the sidelines FUN.
A 53% Increase in Cannabis Net Revenue on Aleafia Health (OTCMKTS: ALEAF)’s Q2 2021 Financial Results Demonstrates the Success of its Expanded Product Portfolio
By Neha Gupta
AUG 25, 2021
https://gentrybusinessleader.com/a-53-increase-in-cannabis-net-revenue-on-aleafia-health-otcmkts-aleafs-q2-2021-financial-results-demonstrates-the-success-of-its-expanded-product-portfolio/
Gaining access to Europe’s legal cannabis market was the most remarkable breakthrough for Aleafia Health (OTCMKTS: ALEAF). It was one of the many activities that contributed to the company’s Q2 2021 financial results.
The most significant shift was a 53% increase of cannabis net revenue from the previous quarter ending at $9.6 million. Increased sales of cannabis across the adult-use, medical and bulk wholesale sales channels played a crucial role in putting together the revenue.
Medical cannabis achieved a $3.3 million net revenue for Q2 2021, a 23% increase over the previous quarter. Adult-use cannabis revenue was at $3.2 million, translating to an 87% increase over the last quarter, while cannabis bulk wholesale sales brought home $3.1 million, compared to $1.9 million previously.
Geeze I hope not! They have the golden goose with the union deal. They just have to onboard the employees and provide them with consistent product. If they need anything it might be more growers but canopy and aurora both suck and have enormous baggage. They would just drag aleafia down. Maybe a deal with a company that knows how to grow consistently good weed….. a thing that eludes both those mentioned so far.
I've wondered about that but if so, why the offering?
Which Canadian LP Will Be The Next Up To Make A Transformative Acquisition?
I think they see the up side here and we are in a very good spot. They awarded warrants (thank you for the correction) so, some dilution but the money comes back to the company and even at a high interest rate it is better than straight dilution. They have a captive audience with the unions and the rest of their operation is gravy.
Those are not shares, they are warrants. At least they have to pay to exercise them.
Let's hope it's a killer deal for them.
Or do you suppose that's what is behind today's PPS rise? Are they trying to drive the PPS up into profit territory for themselves?
The lender accepted a million shares at a value of .32cdn? They see the valueI am getting more as soon as I can
Seems to be quite a wall.
A little surprised Price $0.27 Day's Change 0.04 (17.39%)
Volume(Heavy Day)
Today's volume of 189,226 shares is on pace to be much greater than ALEAF's 10-day average volume of 239,894 shares.
9:57 am ET
They weren't shy about raising it either. Took it down without blinking an eye.
New Money but pummeled, this is all they could raise--->>>Aleafia Health Announces Closing of $10 Million Credit Facility
Canada’s weed sales reach $318M record in June
Nova Scotia’s sales jumped more than any other province
https://mugglehead.com/canadas-weed-sales-reach-318m-record-in-june/
By Kathryn Tindale
Published
2 days ago
Canadians have been out-buying themselves in legal weed this year, with another record set in June for retail cannabis sales.
On Friday, Statistics Canada released preliminary retail sales data, which shows a monthly increase of 1.7 per cent to $318.7 million. This is the fourth consecutive month the country hit record weed sales.
The daily spending average for June is about $10.6 million, and Canada could surpass $3.87 billion in weed sales this year.
Canada’s overall retail sales increased 4.2 per cent in June, primarily led by higher sales at clothing stores. Six provinces saw sales go up, with Ontario and Nova Scotia leading the pack at 9.8 per cent and 16.3 per cent respectively.
Weed sales have also gone up in those two provinces.
Nova Scotia’s sales shot up 10.5 per cent to $8.2 million, the largest jump of any province.
Ontario’s sales rose 8 per cent to $120.1 million, while Ottawa leaped 13.3 per cent to $12.1 million. Toronto’s $43.7 million represents a 5 per cent increase.
Canada’s most populous province has continued to add more retail stores, reaching more than 1,000 as of Friday.
Ontario Cannabis Store
@ONCannabisStore
Aug 20
You can now shop at over 1000 Authorized Cannabis Retailers across Ontario, owned and operated by your local buds. Find a store near you: https://bit.ly/2GZSgh2
https://twitter.com/ONCannabisStore?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1428778948809342978%7Ctwgr%5E%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Fmugglehead.com%2Fcanadas-weed-sales-reach-318m-record-in-june%2F
Large markets dip while weed sales climb in Maritimes and Prairies
Of the four largest weed markets in Canada, Ontario is the only one to bring in higher sales in June.
Alberta’s sales dropped 4.4 per cent to $57.1 million, and Quebec dipped 0.7 per cent to $49.2 million.
Both provinces had cannabis sales steadily increase for most of the year — with the exception of February — before dipping in June.
Sales had been climbing for three months in British Columbia before dropping 4.1 per cent to $44.5 million in June. Vancouver’s sales decreased by 1.4 per cent to $14.4 million. A total of 371 licences have been issued in B.C. so far.
Saskatchewan sold $13 million, up 0.7 per cent from May, and Manitoba’s sales went up 2 per cent to $12.1 million.
It seems the Maritime provinces are faring better in June than the previous month as well.
In addition to improved sales in Nova Scotia, New Brunswick’s went up 3.4 per cent to $6.6 million. Newfoundland and Labrador saw a similar increase of 3.8 per cent to $4.9 million.
Sales for P.E.I and the Yukon haven’t been provided by StatsCan since March.
There weren’t any June numbers for the Northwest Territories either. Nunavut hasn’t had available sales data and currently only has one store.
Canada retail sales data from May has been revised slightly to $313.18 million.
We are in a very unique and almost secret position here. The industry is forced to stay on the fringes. Away from institutional access. The only ones here with us are the hedge funds who love to play their short games here in otc land. The instant this company shows its value they will turn into longs. Noting has changed in the company’s fundamentals. Their prospects are incredible and nobody seems to understand the situation. I am good with it until I can buy more lol!
Yup, I'm seeing it mac.
And yet we are in low .20’s
I saw that too FUN but it seems since then a dump of the stock. And it continues. Guessing that a split is on the horizon after the dump is complete.
One news item I missed while camping at Lake George--->>>Aleafia Health Reports Strong 2021 Second Quarter Financial Results with 53% Sequential Increase in Cannabis Net Revenue
Darn it, I thought the Unifor deal would have made the market happy that is why I held.
I understand that the offer was never lower than my bid, but when a sell-at-the-market order is placed, how does it make any sense to fill that sell order at a bid lower than the highest bid? That’s trading thru the bid in my book. It’s the same thing as having an offer lower than the bid.
It’s MM games. It’s OTC games.
I would bet that the ask always stayed above your bid price of .291. Therefore, it was a "hit or miss" situation for you. You got over 1/2 the shares you wanted and some others were able to buy some shares at a bit lower price. Unfortunately, you don't have a leg to stand on if you were to contest it with your broker since your bid was lower than the ask.
I was .291 bid for 5,000 shares, limit order, today. I was filled in 2,931 shares at 2:30 CST. Then, the following trades occurred:
4,000 traded @ .2901 @ 2:31 CST
1,705 traded @ .29 @ 2:32 CST
300 traded @ .2901 @ 2:32 CST
1,447 traded @ .2907 @ 2:58 CST
Is there any valid explanation for why I didn’t get filled on my entire order?
Or do we chalk this up to “MM privilege” and the “OTC is the wild Wild West”?
Thx FUN but I think I'll be out of town then too. I'll have to check.
Aleafia Health to Announce 2021 Second Quarter Results
Yup, plug that hole.
It sure feels like Aleafia sprung a slow leak.
Seems like good news but not much volume yet.
Aleafia Health Announces the Appointment of Mark J. Sandler as Board Chair
https://aleafiahealth.com/news-releases/aleafia-health-announces-the-appointment-of-mark-j-sandler-as-board-chair/
TORONTO, July 29, 2021 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) a global leader in cannabis wellness products and services, is pleased to announce the appointment of Mark J. Sandler as Chairman of its Board of Directors (the “Board”). He is the longest serving member of the Company’s board, which is composed entirely of independent directors, and chairs its Governance Committee.
Currently senior partner at Cooper, Sandler, Shime, & Bergman LLP, Mr. Sandler is a leading appellate and trial lawyer, as well as an adjudicator and mediator in regulatory matters, including securities litigation. He served three terms as an elected member of the Law Society of Ontario’s governing body.
“Aleafia Health is well positioned to continue on its growth trajectory of the last three years, from a pre-revenue startup to a leading global cannabis company,” said Mr. Sandler. “In supporting the objectives of the company, we will continue to prioritize strong corporate governance, and sustainable growth in the adult-use, medical and international markets.”
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.
Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
I think the biggest question has to be about the union contract. Why does it appear to be doing nothing for the top and bottom line?
Regardless, it appears that we are waiting on the outdoor harvest again.
I thought the indoor cultivation facility was going to help flatten out the monthly revenues.
Something isn't going right?
I guess it might FUN and these folks have so many good things going on why does it remain wallowing down here.
Been gone a week. Closed on the camp and land.
Interesting--->>>Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application
I wonder if this can positively impact Aleafia's revenues? - FUNMAN
KetamineOne Capital Limited
Wed, July 28, 2021, 7:00 AM
5 min read
https://finance.yahoo.com/news/ketamine-one-advances-research-capabilities-110000639.html
The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health
VANCOUVER, British Columbia, July 28, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly-owned contract research organization (“CRO”), KGK Science Inc., (“KGK”) has recently achieved several milestones in its psychedelic research capabilities and significantly expanded its access to patients through further integration with Ketamine One.
Controlled Drugs and Substances Dealer’s Licence:
KGK recently applied for a controlled drugs and substances dealer’s licence under Canada’s Narcotic Control Regulations governing the possession, distribution, sale, clinical studies of and research and development of controlled substances, including Psilocybin, Psilocin, Ketamine, MDMA, LSD, DMT, Mescaline, Salvinorin A, Harmaline and Harmalol.
Subject to the approval of Health Canada, the licence will effectively enable KGK to offer a turn-key solution for third parties to conduct clinical trials involving psychedelic molecules, while also authorizing KGK to act as a centralized distributor for large, multi-location clinical trials.
Pre-Qualification of Canadian Facilities for Clinical Trials:
Additionally, Ketamine One has completed the pre-qualification audits of its Canadian clinics with KGK to prepare for the use of the Company’s facilities in future clinical trials. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study. This direct access to patients and clinics is expected to differentiate KGK from other CROs by providing the opportunity to study patients with differing demographics across various populations, while also shortening recruitment timelines for studies.
The Company has been focused on a swift integration of the medical clinics that Ketamine One previously announced on May 7th as having been acquired from Canabo Medical Corporation, a wholly-owned subsidiary of Aleafia Health Inc. (TSX: AH) (“Aleafia”) together with its other recent acquisition of KGK announced on June 3rd.
Additionally, as previously announced on January 21, 2021, Unifor and Aleafia entered into an exclusive 10-year agreement to support union members, retirees and their eligible dependents that receive medical cannabis insurance coverage clinics through Unifor's collective bargaining agreements. To date, the clinic network has seen over 75,000 unique patients and has conducted extensive research in cannabinoid therapy as it relates to sleeping disorders, opioid reduction and other topics.
Management Commentary:
“Today’s announcements are further evidence of the synergies between our growing clinic network and our contract research offerings,” said Ketamine One’s Interim CEO, Adam Deffett. “KGK will now have the ability to utilize our clinic sites for future trials, gain access to a large patient database and, upon approval, have a narcotic dealers license.
Our goal is that these initiatives will also provide Ketamine One patients with breakthrough treatments through clinical trials and our clinical staff with experience and protocols needed for the eventual expansion of new treatments. We view this as a great opportunity to demonstrate their operational capabilities while also earning a new revenue stream from Ketamine One,” added Mr. Deffett.
General Research:
The Company has engaged General Research GmbH (“GR”) to increase its exposure to investors in Europe. The services agreement with GR has an aggregate cash cost of 40,000 Euros, has an initial term of two months, and such term may be extended for subsequent periods. GR will not receive any securities of the Company as compensation, and it does not currently own any securities of Ketamine One. Ketamine One and GR are unrelated and unaffiliated entities; GR is arm’s length to the Company.
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 16 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.
On behalf of:
KETAMINE ONE
"Adam Deffett"
Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
Ya, I try to share her videos when I see them. She seems like she is just sharing her experience, I like that.
Imagine that; cannabis made a bit of a come back today.
And it looks like Aleafia is only going in one direction. Geeezzz, I bet on the wrong pony and am sorry I got others to join me.
Well stated and agreed.
Looking forward to a strong sector rebound before I’m “planted”.
GL!
She made a few product review videos of Aleafia products. You and I are 2 of the 11 viewers so far.
Diogenes, Let's hope someone gives a hoot. Moving forward introducing new brands is great, but without marketing, it's as if mgmt is just throwing the spaghetti at the wall and hoping it sticks as well as Grey Goose Vodka did, and they did a ton of marketing.
Better analogies are cigars and scotches. In an age where smoking is frowned upon it's tough to find a breakout success. Maybe Cohiba and Macanudo rings a bell with some people. Scotch brands are even more elusive. Maybe most people know of Jonnie Walker, but aficionados gravitate to single malts.
All I am saying is releasing great new strains that appeals to experienced cannabis aficionados isn't going to move the needle unless it's the "next Grey Goose".
Aleafia has to so more with social marketing. Other producers are doing it. Aleafia is pretty much ignoring brand building and creating demand.
I know there are advertising prohibitions, but other companies are doing it within the legal allowable parameters. Aleafia has to do more of it and get better at it.
Aleafia Health Launches Premium Cannabis Brand Nith & Grand
* Nith & Grand tailored to cannabis aficionados with discerning taste, and will feature craft flower and premium concentrates
* Initial launch features TF Pink Kush Live Resin vape cartridges
* Strengthened product portfolio contributing to meaningful quarterly
sales growth across all sales channels
TORONTO, July 19, 2021 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce the launch of its premium cannabis brand Nith & Grand.
Featuring hang dried, hand trimmed, small batch dried flower, and premium concentrates, Nith & Grand appeals to experienced cannabis aficionados.
The initial launch features TF Pink Kush Live Resin vape cartridges, which comprises a hydrocarbon extraction process utilizing fresh-frozen cannabis flower that preserves the strain’s natural flavour, aroma and terpene profile. The new product features the highly sought after and not yet widely available TF Pink Kush strain, and is now available in adult-use markets.
“Nith & Grand completes our highly differentiated brand portfolio, allowing us to reach the growing market for premium, craft cannabis products. With a collection of highly sought after cultivars and six years operating our craft cultivation facility in Paris, Ont., we are perfectly situated to delight cannabis connoisseurs,” said Aleafia Health CEO Geoffrey Benic.
“Aleafia Health can now boast one of the strongest and most diverse product portfolios in the Canadian cannabis industry. This along with scaling our production has directly led to strong sequential sales growth in the adult-use, wholesale, and medical sales channels, both domestically and internationally, in our most recent quarter.”
Nith & Grand’s namesake is a tribute to our product innovation facility’s home community of Paris, Ont., whose scenic downtown core is centred around the confluence of the Nith and Grand rivers.
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.
Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Aleafia Health Launches Premium Cannabis Brand Nith & Grand
https://www.globenewswire.com/news-release/2021/07/19/2264756/0/en/Aleafia-Health-Launches-Premium-Cannabis-Brand-Nith-Grand.html
This is big
+A A -A Alto contraste
COVID-19
Literatura global sobre doença de coronavírus
??????? ?? (??) english français ??????? español português
Notícias/Atualização/Ajuda
Busca Avançada
Pesquisar
Home
Pesquisa
Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
Este artigo é um Preprint
Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
Dongbo Yang; Long Chi Nguyen; Vlad Nicolaescu; Thomas Best; Shaonong Chen; J. Brent Friesen; Nir Drayman; Adil Mohamed; Christopher Dann; Diane Silva; Haley Gula; Krysten A. Jones; J. Michael Millis; Bryan C. Dickinson; Savas Tay; Scott A. Oakes; Guido F. Pauli; David O. Meltzer; Glenn Randall; Marsha Rich Rosner.
Preprint | bioRxiv | ID: ppbiorxiv-432967
ABSTRACT
The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway. A cohort of human patients previously taking CBD had significantly lower SARS-CoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population. This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection.
Video opinion on Noon & Night Aleafia’s new rollon cbd product. She says it helped :)
I do not think you will have to wait much longer :)
Don’t get me wrong. I’ve been trying to stay positive since 2017 but it only get’s worst and worst. I have five figures invested and been trying to recover at least $15k. No luck yet
I’m trying to stay positive.
Realistically, I’m in the red but add as I please as faith for future growth (even if undeserved) remains.
GLTA
Only with this stock! PR comes in and it drops
Followers
|
86
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3369
|
Created
|
12/08/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |